Literature DB >> 19252832

Identification of target and function specific antibodies for effective drug delivery.

Yu Zhou1, James D Marks.   

Abstract

Phage antibody technology is a powerful approach for generating human antibodies to virtually any target antigen. For many therapeutic applications, it is useful to generate antibodies that bind to cell-surface receptors in a manner where binding results in internalization of the antibody. This allows use of the antibody to deliver toxic payloads intracellularly to achieve a therapeutic effect. Here we describe how phage antibody libraries can be directly selected on tumor cell lines to generate antibodies binding cell-surface receptors and which are rapidly internalized upon binding. Protocols are provided showing how to (1) directly select internalizing antibodies from phage antibody libraries; (2) screen phage antibodies in a high-throughput flow cytometry assay for binding to the tumor cell line used for selection; (3) identify the antigen bound by the phage antibody using immunoprecipitation and mass spectrometry; and (4) verify and quantitate such that phage antibodies are internalized.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19252832     DOI: 10.1007/978-1-59745-554-1_7

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  3 in total

1.  A novel in vivo method for isolating antibodies from a phage display library by neuronal retrograde transport selectively yields antibodies against p75(NTR.).

Authors:  Hiroaki Tani; Jane K Osbourn; Edward H Walker; Robert A Rush; Ian A Ferguson
Journal:  MAbs       Date:  2013-04-02       Impact factor: 5.857

2.  Identifying blood-brain-barrier selective single-chain antibody fragments.

Authors:  Angela R Jones; C Christopher Stutz; Yu Zhou; James D Marks; Eric V Shusta
Journal:  Biotechnol J       Date:  2014-03-18       Impact factor: 4.677

3.  Antibody screening using a human iPSC-based blood-brain barrier model identifies antibodies that accumulate in the CNS.

Authors:  Julia V Georgieva; Loukas I Goulatis; Charles C Stutz; Scott G Canfield; Hannah W Song; Benjamin D Gastfriend; Eric V Shusta
Journal:  FASEB J       Date:  2020-07-30       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.